Gabriel Roberti, MD
@Gabriel_Pathol
Pathologist interested in Urologic and Molecular Pathology | Postdoc Research Fellow @BrighamWomens and @HarvardMed
So proud to be part of this incredible research team! #KCRS25 #pathology #kidneycancer @kidneycan
Insightful discussions, cutting edge research, great speakers, multidisciplinary approach & an amazing audience- perfect #kidneycancer meeting @kidneycan #KCRS2025 #genomics #pathology #cancer
Molecular and Therapeutic Landscape of Non-Clear Cell Renal Cell Carcinoma: 🧬🧬🧬Diverse subtypes, unique genetics, unpredictable responses. @NatRevUrol @OncoAlert @kidneycan @IKCCorg @KidneyCancer @MehrazinMD rdcu.be/ewjT8
Enjoy Kidney Cancer's Special Pathology Edition. A great set of [open access] RCC reviews; also, sarcomas, benign tumors, molecular changes, familial syndromes, grading/staging. Great for patients, clinicians, researchers & pathologists.🔬#gupath @urotoday journals.sagepub.com/toc/kcaa/9/1_s…
This helpful infographic from @genome_gov explains the challenges of sequencing highly repetitive DNA and the technological advances that were needed to generate the first truly complete (gapless) human genome sequence. I encourage you to check it out! genome.gov/about-genomics…
Assessment and classification of sex cord‐stromal tumours of the testis: recommendations from the testicular sex cord‐stromal tumour (TESST) group, an Expert Panel of GUPS and ISUP- Acosta - Histopathology - Wiley Online Library #openaccess onlinelibrary.wiley.com/doi/10.1111/hi…
🧾 Cheat Sheet on Follow-up for NMIBC 🔹 Risk-based surveillance 🔹 Lifelong follow-up for high-risk patients 🔹 Role of cytology & markers 🔍 No substitute for cystoscopy Download Cheat Sheet: uroweb.org/guidelines/non… #BladderCancer #NMIBC #EAUguidelines
Unique pattern of an uncommon #testis tumor. What’s is your diagnosis #GUPath tweeps? #OnePicDx Answer in comment👇👇👇
Big news! Massachusetts General Hospital and Brigham and Women’s Hospital have been ranked #1 and #2 globally for research impact among healthcare institutions by the 2024 @NatureIndex. Proud to be part of a pathology department at the forefront of discovery! 🧪🔬 #PathTwitter
𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬𝟗 is a process in which clustered regularly interspaced short palindromic repeats (CRISPR) — small remnants of viral DNA from previous viral infection that are embedded in bacterial DNA — generate guide RNAs, which are used together with a DNA-cutting enzyme…
Advances in molecular pathology and therapy of non-small cell lung cancer 💫An exceptionally comprehensive review (72 pages 👀) Algorithms👇 nature.com/articles/s4139…
🎯 Testicular cancer is the most common solid tumor in young men (15–40y), with >90% being germ cell tumors (GCTs). Early diagnosis + tailored treatment = excellent outcomes (5y OS: 99% in stage I). Survivorship matters 👉🏻 fertility, CV risk & QoL must guide care. 📖…
A comprehensive review about the role of tumor microenvironment on the immunotherapy response! @OncoAlert @NatureCancer #Cancer #Oncology #MedTwitter nature.com/articles/s4301…
📢 A new era in head & neck cancer care begins. #FDA approves #pembrolizumab as the first immunotherapy for perioperative use in resectable LA-HNSCC. Neoadjuvant + adjuvant strategy now reshapes standard of care. 👇See the full breakdown: 📊 #KEYNOTE689 | 📆 June 12, 2025…
🎯 Too many targets. Too little time. ⏳ On June 11, 2025, Taletrectinib received FDA approval for advanced ROS1+ NSCLC. With impressive ORR and CNS activity, it reshapes the ROS1 landscape. 🧠 To keep track of all genetically driven NSCLC therapies, we created this clean,…
.@DrChoueiri takes the stage to present data from the phase 1 ARC-20 trial that shows that the combination of HIF2 inhibitor casdatifan plus cabo has promising clinical activity (cORR 46%) and an acceptable safety profile in pretreated pts w/ mRCC. #ASCO25 @ASCO @OncoAlert
HER2-positive invasive breast carcinoma (NST). HER2 gene-protein assay: brightfield tricolor assay (combined ICH+ISH) for the visualization of HER2 protein (brown), the HER2 gene (black), and chromosome 17 centromere (CEN17) (red).
In this #AMPtutorials, we will discuss a very important topic in the practice of routine molecular diagnostics: microsatellite instability (MSI) and deficient mismatch repair (dMMR) testing. (Thread 🧵1/11). Disclaimer: This educational resource does not constitute medical or…
Kidney tumors - updates & newer entities (Basic facts for residents) Molecularly defined entities involving TFE3, TFEB, ELOC, ALK, SMARCB1, SDH, FH etc. Evolving classification of papillary renal cell carcinoma. #MakeSurgiPathEasy #RenalTumorsUpdates